Compare FBRT & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FBRT | BWAY |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | Israel |
| Employees | 223 | 129 |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 648.8M | 578.5M |
| IPO Year | N/A | N/A |
| Metric | FBRT | BWAY |
|---|---|---|
| Price | $8.17 | $14.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $11.50 | ★ $13.25 |
| AVG Volume (30 Days) | ★ 1.2M | 77.4K |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | ★ 15.83% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.34 | $309.69 |
| Revenue Next Year | $4.95 | $26.21 |
| P/E Ratio | ★ $13.56 | $81.98 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.75 | $11.35 |
| 52 Week High | $11.84 | $26.63 |
| Indicator | FBRT | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 48.63 | 46.25 |
| Support Level | N/A | $14.30 |
| Resistance Level | $8.51 | $14.85 |
| Average True Range (ATR) | 0.22 | 0.60 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 60.43 | 28.33 |
Franklin BSP Realty Trust Inc is a private real estate investment trust that originates, acquires, and manages a diversified portfolio of commercial real estate debt, and first mortgage loans. secured by properties located in the United States. The Company's operations are organized into two business units: (i) Commercial Real Estate Financing, and (ii) Agency Business. Its four reporting segments are as follows: The real estate debt business, The Agency Business, The commercial real estate conduit business, and The real estate owned business.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.